Last reviewed · How we verify
Lactobacillus plantarum
Lactobacillus plantarum is a probiotic bacterium that colonizes the gut and modulates the intestinal microbiota and immune system to promote gastrointestinal and systemic health.
Lactobacillus plantarum is a probiotic bacterium that colonizes the gut and modulates the intestinal microbiota and immune system to promote gastrointestinal and systemic health. Used for Gastrointestinal health and microbiota modulation, Diarrhea prevention and treatment, Irritable bowel syndrome.
At a glance
| Generic name | Lactobacillus plantarum |
|---|---|
| Sponsor | Shenzhen People's Hospital |
| Drug class | Probiotic |
| Modality | Biologic |
| Therapeutic area | Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
As a lactic acid-producing bacterium, L. plantarum ferments carbohydrates to lower intestinal pH, inhibit pathogenic bacteria, and strengthen the intestinal barrier through tight junction protein expression. It also stimulates innate and adaptive immune responses via pattern recognition receptors, promoting anti-inflammatory cytokine production and enhancing mucosal immunity.
Approved indications
- Gastrointestinal health and microbiota modulation
- Diarrhea prevention and treatment
- Irritable bowel syndrome
Common side effects
- Gastrointestinal bloating
- Mild abdominal discomfort
- Flatulence
Key clinical trials
- Effect of Probiotic Supplementation on Endothelial Function II (NA)
- Clinical Trial of Lactiplantibacillus Plantarum Dad-13 on Gut Microbiota Profile and Performance in Adolescent Athletes (NA)
- Synbiotic to Attenuate Resorption of the Skeleton (NA)
- Effects of Probiotic Supplementation on Stress and Anxiety in Students (NA)
- Synbiotic Supplement With Botanical Extracts for Gut Microbiota Balance in Irritable Bowel Syndrome (NA)
- Reducing Innate Inflammation in New Onset Type 1 Diabetes (PHASE2)
- The Effect of the Probiotic Strains on Bone Mineral Density in Postmenopausal Women (NA)
- Impact of Supplementation With Synbiotics and Prebiotics on Cognitive Decline Associated With Neoadjuvant Chemotherapy in First-line Patients With Breast Cancer (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lactobacillus plantarum CI brief — competitive landscape report
- Lactobacillus plantarum updates RSS · CI watch RSS
- Shenzhen People's Hospital portfolio CI